Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

NCT05581719 is registered in ClinicalTrials.gov with Enlivex Therapeutics RDO Ltd. as lead sponsor.

NCT NCT05581719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05581719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Lead sponsor
Enlivex Therapeutics RDO Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
November 15, 2022
Completion date
April 15, 2024
Enrollment
14 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal cancer, peritoneal metastases, solid tumor